Latest Period
Q4 2025
Security Snapshot
Apogee Therapeutics, Inc. - COMMON STOCK (APGE) Institutional Ownership
CUSIP: 03770N101
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
206
Shares (Excl. Options)
69,771,331
Price
$75.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- APGE on Nasdaq
- Shares outstanding
- 61,257,262
- Price per share
- $86.27
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 69,771,331
- Total reported value
- $5,266,434,045
- % of total 13F portfolios
- 0.01%
- Share change
- +9,434,359
- Value change
- +$762,006,154
- Number of holders
- 206
- Price from insider filings
- $86.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- APGE - Apogee Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 03770N101.
- 206 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 206 to 52 between Q4 2025 and Q1 2026.
- Reported value moved from $5,266,434,045 to $271,601,580.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 206 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03770N101?
CUSIP 03770N101 identifies APGE - Apogee Therapeutics, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03770N101:
Significant Owners of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17% | +50% | $866,203,754 | +$343,190,907 | 10,291,220 | +66% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| FMR LLC | 15% | $266,406,847 | 6,907,100 | FMR LLC | 30 Jun 2025 | |||
| Fairmount Funds Management LLC | 10% | 0% | $482,139,697 | +$51,168,083 | 6,764,974 | +12% | Peter Evan Harwin | 26 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 8.7% | -17% | $374,980,215 | -$10,946,319 | 4,746,585 | -2.8% | Wellington Management Group LLP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.9% | -18% | $214,255,663 | 2,712,097 | 0% | RTW Investments, LP | 31 Dec 2025 | |
| BlackRock, Inc. | 5.5% | $109,396,539 | 2,518,725 | BlackRock, Inc. | 30 Jun 2025 | |||
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4.7% | $85,757,284 | 2,158,502 | DRIEHAUS CAPITAL MANAGEMENT LLC | 30 Sep 2025 |
As of 31 Dec 2025, 206 institutional investors reported holding 69,771,331 shares of Apogee Therapeutics, Inc. - COMMON STOCK (APGE). This represents 114% of the company’s total 61,257,262 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) together control 92% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VR ADVISER, LLC | 14% | 8,493,321 | 0% | 32% | $641,075,869 |
| FMR LLC | 13% | 8,225,038 | +19% | 0.03% | $620,825,834 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.7% | 4,746,585 | +0.48% | 0.06% | $358,272,236 |
| BlackRock, Inc. | 6.2% | 3,783,994 | +41% | 0% | $285,615,865 |
| VANGUARD GROUP INC | 4.7% | 2,857,824 | +27% | 0% | $215,708,556 |
| T. Rowe Price Investment Management, Inc. | 4.5% | 2,732,456 | +189522% | 0.13% | $206,246,000 |
| RTW INVESTMENTS, LP | 4.4% | 2,712,097 | 0% | 2.1% | $204,709,082 |
| PERCEPTIVE ADVISORS LLC | 3.8% | 2,330,651 | +72% | 3.2% | $175,917,537 |
| Driehaus Capital Management LLC | 3.6% | 2,183,704 | +1.2% | 1.1% | $164,825,978 |
| JANUS HENDERSON GROUP PLC | 3.4% | 2,062,604 | +324% | 0.07% | $155,697,275 |
| Fairmount Funds Management LLC | 3.3% | 2,048,647 | 0% | 12% | $154,631,876 |
| STATE STREET CORP | 2.8% | 1,690,186 | +2.1% | 0% | $127,575,239 |
| JPMORGAN CHASE & CO | 2.2% | 1,373,066 | +21% | 0.01% | $103,639,021 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2% | 1,237,135 | +65% | 0.01% | $93,380,000 |
| Affinity Asset Advisors, LLC | 2% | 1,234,926 | +5.2% | 6.7% | $93,212,214 |
| Paradigm Biocapital Advisors LP | 1.8% | 1,123,243 | -26% | 2.3% | $84,782,382 |
| ALLIANCEBERNSTEIN L.P. | 1.8% | 1,093,657 | -23% | 0.03% | $82,549,230 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,059,085 | +19% | 0% | $79,957,396 |
| UBS Group AG | 1.6% | 974,826 | +22% | 0.01% | $73,579,866 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.5% | 890,665 | -8.2% | 0.1% | $67,227,394 |
| MORGAN STANLEY | 1.5% | 890,264 | +91% | 0% | $67,197,243 |
| BANK OF AMERICA CORP /DE/ | 1.3% | 793,695 | +101% | 0% | $59,908,098 |
| CITADEL ADVISORS LLC | 1.3% | 766,981 | -34% | 0.04% | $57,891,726 |
| Remedium Capital Partners, LLC | 0.95% | 583,591 | 0% | 26% | $44,050,000 |
| JENNISON ASSOCIATES LLC | 0.94% | 578,627 | 0.03% | $43,674,766 |
Institutional Holders of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,227,288 | $271,601,580 | +$39,161,941 | $84.17 | 52 |
| 2025 Q4 | 69,771,331 | $5,266,434,045 | +$762,006,154 | $75.48 | 206 |
| 2025 Q3 | 59,584,020 | $2,367,665,644 | +$56,487,603 | $39.73 | 173 |
| 2025 Q2 | 57,837,483 | $2,511,890,310 | -$147,322,983 | $43.43 | 180 |
| 2025 Q1 | 61,488,037 | $2,301,755,351 | +$131,273,115 | $37.36 | 165 |
| 2024 Q4 | 57,873,775 | $2,621,627,227 | +$63,332,544 | $45.30 | 156 |
| 2024 Q3 | 56,092,373 | $3,292,239,932 | +$134,148,823 | $58.74 | 137 |
| 2024 Q2 | 54,152,101 | $2,130,892,019 | -$9,800,456 | $39.35 | 137 |
| 2024 Q1 | 52,915,146 | $3,516,219,943 | +$778,331,224 | $66.45 | 137 |
| 2023 Q4 | 41,768,396 | $1,163,676,392 | +$48,111,524 | $27.94 | 85 |
| 2023 Q3 | 40,111,211 | $848,653,526 | +$848,653,497 | $21.30 | 73 |